Loading
Latest filing published 13 Jan 2026 for LISATA THERAPEUTICS, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David J. Mazzo, listed as chief executive, appears in our data through filings on Lisata Therapeutics, Inc. shares, published by SEC (Form 4). In total, 13 filings cover trades dated from 25 January 2016 to 9 January 2026.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Most recently, on 13 January 2026, the filings show a share grant in Lisata Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations